Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | STS | P08842 | 5/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489650 | 0.77 | MAPT (0.43) | MEN1KMT2A | |
| SCHEMBL3489718 | 0.74 | TSHR (0.45) | MEN1KMT2ASTSKDM1A | |
| SCHEMBL3489409 | 0.72 | MEN1 (0.42) | MEN1KMT2ASTSJAK2JAK1 | |
| SCHEMBL1003450 | 0.72 | USP2 (0.44) | — | |
| SCHEMBL3657178 | 0.72 | MEN1 (0.40) | MEN1KMT2ASTSKDM1AANO1 | |
| SCHEMBL391708 | 0.71 | USP2 (0.45) | MEN1KMT2A | |
| SCHEMBL392092 | 0.70 | USP2 (0.44) | — | |
| SCHEMBL1001879 | 0.69 | SMN1; SMN2 (0.57) | MEN1KMT2ASTS | |
| SCHEMBL3489801 | 0.69 | GAA (0.39) | MEN1KMT2AKDM1A | |
| SCHEMBL16936414 | 0.68 | MEN1 (0.51) | MEN1KMT2ASTSCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | MEN1 1655/4885KMT2A 1414/4885STS 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.